Medicina, Volume 60, Issue 11
2024 November - 183 articles
Cover Story: SGLT2 inhibitors (SGLT2-i) demonstrate the potential to slow atherosclerosis progression by reducing inflammation and oxidative stress, independent of glucose control. They lower proinflammatory cytokines, enhance endothelial function, and suppress oxidative stress while also promoting autophagy, stabilizing atherosclerotic plaques, and improving mitochondrial function. These properties provide cardiovascular and kidney protection in type 2 diabetes. SGLT2-i may also offer neuroprotective effects in diabetic neuropathy by improving nerve conduction and clinical symptoms. Despite limited studies on diabetic foot and peripheral artery disease, their anti-inflammatory and immunomodulatory effects suggest therapeutic potential, warranting further research to optimize their use and assess long-term benefits. View this paper - Issues are regarded as officially published after their release is announced to the table of contents alert mailing list .
- You may sign up for email alerts to receive table of contents of newly released issues.
- PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader to open them.